One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues ...

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

Boston-based Ginkgo Bioworks has canceled plans to move into a 250K SF lab data center and will exit two Cambridge locations ...

Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors. Ginkgo Bioworks Holdings, Inc.

TD Cowen analyst Brendan Smith maintained a Buy rating on Ginkgo Bioworks Holdings (DNA – Research Report) today and set a price target of $10.00. Brendan Smith’s rating is based on several strategic ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs ...

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...

BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of ...